drugset
drugset / Trial / NCT02176577

Study to Determine the Pharmacokinetics of Product 0405

NCT02176577 ↗

Phase 3 Withdrawn Fougera Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.

Timeline

Start
2012-06
Primary completion
2013-05
Completion
2013-05

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Product 0405 Unknown — Topical

Indications

atopic eczema